Neutrophil to Lymphocyte Ratio as a Predictor of Poor Prognosis in Metastatic Pancreatic Cancer Patients Treated with Nab-Paclitaxel plus Gemcitabine: A Propensity Score Analysis

Table 3

Univariate and multivariate analysis PFS.

Variable	Univariate			Multivariate
	HR	95% CI	value	HR	95% CI	value
Age (≥66 years versus <66 years)	0.86	0.5–1.5	0.58
Gender (female versus male)	1.1	0.6–1.9	0.71
Tumor location (nonhead versus head)	1.3	0.7–2.2	0.37
Karnofsky performance status score (100–80% versus 70–60%)	0.5	0.2–1	0.08
CA19.9 basal (≥59 ULN versus <59 ULN)	0.8	0.4–1.5	0.5
CA19.9 reduction (<50% versus ≥50%)	2.44	1.3–4.6	0.006	3.22	1.6–6.4	0.001
Stent (yes versus no)	0.69	0.37–1.29	0.24
N/L ratio (≥5 versus <5)	1.9	1.0–3.4	0.036	2.77	1.3–5.7	0.006
Liver metastasis	0.5	0.3–0.9	0.038	0.5	0.2–1.0	0.05